"Pfizer beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected. The stock gapped up roughly 12.6% in pre-market trading, reflecting strong investor validation of both the beat and the company's reaffirmed full-year guidance paired with a raised EPS outlook. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion but raised EPS guidance to $3.00 to $3.15 from prior guidance."
"Non-COVID revenue grew 4% operationally, driven by strength in key franchises. Eliquis, the anticoagulant, surged 22% operationally. Vyndaqel, used for cardiac amyloidosis, climbed 7%. These are the growth engines that matter going forward. Paxlovid, by contrast, collapsed 55% operationally, and Comirnaty vaccine revenue fell 20%. That's expected. The real test is whether the base business can sustain momentum as legacy COVID products fade."
Pfizer reported adjusted EPS of $0.87 versus $0.64 expected and revenue of $16.65 billion versus $16.50 billion expected, prompting a roughly 12.6% pre-market stock gap. Net income fell 20.84% year over year to $3.54 billion and reported revenue declined 5.92% from $17.70 billion, reflecting post-pandemic normalization. Non-COVID revenue grew 4% operationally, led by Eliquis (up 22%) and Vyndaqel (up 7%), while Paxlovid and Comirnaty revenue declined sharply. Management reaffirmed 2025 revenue guidance of $61.0–$64.0 billion and raised EPS guidance to $3.00–$3.15, citing a U.S. government agreement and strategic portfolio moves.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]